2026-09-18T10:43:38Zhttps://gredos.usal.es/oai/request
oai:gredos.usal.es:10366/1368962026-02-19T09:50:46Zcom_10366_135255com_10366_4512com_10366_3823col_10366_135256
Gestión del Repositorio Documental de la Universidad de Salamanca author Bárcena Carrasco, Paloma author Jara Acevedo, María author Tabernero, María Dolores author López, Antonio author Sánchez, María Luz author García Montero, Andrés Celestino author Muñoz-García, Noemí author Vidriales Vicente, María Belén author Paiva, Artur author Lecrevisse, Quentin author Lima, Margarida author Langerak, Anton W author Böttcher, Sebastian author van Dongen, Jacques J. M. author Orfao de Matos Correia e Vale, José Alberto author Almeida Parra, Julia María 2018-02-06T07:56:41Z 2018-02-06T07:56:41Z 2015-11-06 Oncotarget. 2015 Dec 15;6(40):42938-51 http://hdl.handle.net/10366/136896 10.18632/oncotarget.5480 [EN]Currently, the lack of a universal and specific marker of clonality hampers the diagnosis and classification of chronic expansions of natural killer (NK) cells. Here we investigated the utility of flow cytometric detection of aberrant/altered NK-cell phenotypes as a surrogate marker for clonality, in the diagnostic work-up of chronic lymphoproliferative disorders of NK cells (CLPD-NK). For this purpose, a large panel of markers was evaluated by multiparametric flow cytometry on peripheral blood (PB) CD56(low) NK cells from 60 patients, including 23 subjects with predefined clonal (n = 9) and polyclonal (n = 14) CD56(low) NK-cell expansions, and 37 with CLPD-NK of undetermined clonality; also, PB samples from 10 healthy adults were included. Clonality was established using the human androgen receptor (HUMARA) assay. Clonal NK cells were found to show decreased expression of CD7, CD11b and CD38, and higher CD2, CD94 and HLADR levels vs. normal NK cells, together with a restricted repertoire of expression of the CD158a, CD158b and CD161 killer-associated receptors. In turn, NK cells from both clonal and polyclonal CLPD-NK showed similar/overlapping phenotypic profiles, except for high and more homogeneous expression of CD94 and HLADR, which was restricted to clonal CLPD-NK. We conclude that the CD94(hi)/HLADR+ phenotypic profile proved to be a useful surrogate marker for NK-cell clonality. eng Attribution-NonCommercial-NoDerivs 3.0 Unported Chronic lymphoproliferative disorders of NK-cells Oncology NK-cell clonality Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality info:eu-repo/semantics/article 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 URL https://gredos.usal.es/bitstream/10366/136896/1/Barcena_et_al_OncoTarget_2015.pdf File MD5 c26b60b692ebe28e3c3ee0bd603cb23c 4176833 application/pdf Barcena_et_al_OncoTarget_2015.pdf URL https://gredos.usal.es/bitstream/10366/136896/2/Barcena_et_al_Suppl_OncoTarget_2015.pdf File MD5 4fab07faa2b2949eec8a381ba9d648cb 1684093 application/pdf Barcena_et_al_Suppl_OncoTarget_2015.pdf URL https://gredos.usal.es/bitstream/10366/136896/10/Barcena_et_al_OncoTarget_2015.pdf.txt File MD5 b16db3295ce57fc5b83289e26b4844c4 59858 text/plain Barcena_et_al_OncoTarget_2015.pdf.txt URL https://gredos.usal.es/bitstream/10366/136896/12/Barcena_et_al_Suppl_OncoTarget_2015.pdf.txt File MD5 f6a16cc48eb6a5cd6cae378083d8ec5b 1811 text/plain Barcena_et_al_Suppl_OncoTarget_2015.pdf.txt